- $9.62bn
- $10.04bn
- $2.71bn
U.S. STOCKS ON THE MOVE -VF Corp, Biogen, AbbVie
US STOCKS ON THE MOVE-SpaceX, Humana, AbbVie
U.S. STOCKS ON THE MOVE-SpaceX, Humana, Crescent Energy
MedTech growth concerns likely to overshadow Q3 results, Leerink says
Brief: Insulet Corporation Enters Ninth Amendment To Credit Agreement On Sept 21, 2026
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
U.S. STOCKS ON THE MOVE-Walt Disney, Alphabet, Kraft Heinz
U.S. STOCKS ON THE MOVE-Wynn Resorts, Griffon, Kratos Defense, Amgen
Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall (updated)
Insulet Corporation reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cencora, Charles River, Twist Bioscience
Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall
U.S. STOCKS ON THE MOVE-Arista Networks, CVS, Eli Lilly, Phillips 66
Insulet falls after lowering 2026 revenue growth forecast
Insulet Q2 revenue beats on higher Omnipod sales
Brief: US FDA Classifies Insulet Omnipod Pods Recall As Class I Due To Serious Injury Risk
U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers
Brief: FDA Says CDRH Is Issuing Early Alert Of Potentially High-Risk Insulin Pump Issue From Insulet
Brief: Insulet Announces U.S. Rollout Of Enhanced Omnipod® 5 Algorithm And Expands Compatibility With Abbott’S Freestyle Libre 3 Plus Sensor